Correct!

4. 1 + 3

 

Mycobacterium avium-intracellulare is most common NTM isolated from bronchiectasis patients (2). However, Mycobacterium abscessus and Mycobacterium kansasii are increasing in prevalence in recent studies.

The largest study described 154 patients with rapidly growing mycobacterial infection, and 119 (82%) of 146 respiratory isolates identified were Mycobacterium abscessus (3). Mycobacterium abscessus is inherently multidrug resistant and, therefore, challenging to treat. There have been no controlled studies conducted for the treatment of rapidly growing mycobacteria infection. Current treatment recommendations include multidrug therapy with combinations of intravenous and oral antibiotics and/or surgery.

 

Our patient was Mycobacterium abscessus was only sensitive to amikacin. She was treated with IV tigecycline and inhaled amikacin. She has modest clinical improvement.

 

References

  1. Lynch DA. Lung disease related to collagen vascular disease. J Thorac Imaging. 2009;24(4):299-309. [CrossRef] [PubMed]
  2. Wilczynska MM, Condliffe AM, McKeon DJ. Coexistence of bronchiectasis and rheumatoid arthritis: revisited. Respir Care. 2013;58(4):694-701. [CrossRef] [PubMed]
  3. Jarand J, Levin A, Zhang L, Huitt G, Mitchell JD, Daley CL. Clinical and microbiologic outcomes in patients receiving treatment for Mycobacterium abscessus pulmonary disease. Clin Infect Dis. 2011;52(5):565-71. [CrossRef] [PubMed] 

Home/Pulmonary